French biotech stock soars 34% after new data on experimental medicine

Abivax (ABVX) surged 34% Tuesday after releasing new clinical data on its experimental treatment for bowel disease. The French biotech's rally reversed sharp declines earlier in the month tied to the same trial.

The company disclosed fresh results on its lead drug candidate, though the specifics of the data were not detailed in the initial report. The Tuesday pop follows investor concern that emerged when earlier trial information surfaced, suggesting volatility around the program has been extreme within a single month.

ABVX's swing from steep losses to a double-digit gain underscores the binary nature of clinical-stage biotechs, where trial readouts can dramatically reset valuations in a single session. The stock's intra-month whipsaw reflects heightened sensitivity to any incremental disclosure on the bowel disease program, which appears to be the company's primary value driver.